Logo image of ALSGD.PA

SPINEGUARD SA (ALSGD.PA) Stock Fundamental Analysis

EPA:ALSGD - Euronext Paris - Matif - FR0011464452 - Common Stock - Currency: EUR

0.0899  0 (-3.64%)

Fundamental Rating

1

ALSGD gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 57 industry peers in the Health Care Equipment & Supplies industry. ALSGD may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ALSGD is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALSGD had negative earnings in the past year.
In the past year ALSGD has reported a negative cash flow from operations.
In the past 5 years ALSGD always reported negative net income.
In the past 5 years ALSGD always reported negative operating cash flow.
ALSGD.PA Yearly Net Income VS EBIT VS OCF VS FCFALSGD.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1M -2M -3M -4M

1.2 Ratios

Looking at the Return On Assets, with a value of -37.45%, ALSGD is doing worse than 78.95% of the companies in the same industry.
ALSGD has a Return On Equity of -78.95%. This is in the lower half of the industry: ALSGD underperforms 78.95% of its industry peers.
Industry RankSector Rank
ROA -37.45%
ROE -78.95%
ROIC N/A
ROA(3y)-32.05%
ROA(5y)-28.87%
ROE(3y)-64.95%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALSGD.PA Yearly ROA, ROE, ROICALSGD.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K 30K

1.3 Margins

ALSGD's Gross Margin of 70.80% is fine compared to the rest of the industry. ALSGD outperforms 78.95% of its industry peers.
ALSGD's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ALSGD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.62%
GM growth 5Y-2.09%
ALSGD.PA Yearly Profit, Operating, Gross MarginsALSGD.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

0

2. Health

2.1 Basic Checks

ALSGD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALSGD has been increased compared to 1 year ago.
ALSGD has more shares outstanding than it did 5 years ago.
ALSGD has a worse debt/assets ratio than last year.
ALSGD.PA Yearly Shares OutstandingALSGD.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ALSGD.PA Yearly Total Debt VS Total AssetsALSGD.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

ALSGD has an Altman-Z score of -6.19. This is a bad value and indicates that ALSGD is not financially healthy and even has some risk of bankruptcy.
ALSGD has a Altman-Z score of -6.19. This is amonst the worse of the industry: ALSGD underperforms 85.96% of its industry peers.
A Debt/Equity ratio of 0.52 indicates that ALSGD is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.52, ALSGD is in line with its industry, outperforming 42.11% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Altman-Z -6.19
ROIC/WACCN/A
WACC8.11%
ALSGD.PA Yearly LT Debt VS Equity VS FCFALSGD.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M 6M

2.3 Liquidity

ALSGD has a Current Ratio of 0.97. This is a bad value and indicates that ALSGD is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.97, ALSGD is not doing good in the industry: 75.44% of the companies in the same industry are doing better.
A Quick Ratio of 0.69 indicates that ALSGD may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.69, ALSGD is doing worse than 70.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.97
Quick Ratio 0.69
ALSGD.PA Yearly Current Assets VS Current LiabilitesALSGD.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.95% over the past year.
Looking at the last year, ALSGD shows a small growth in Revenue. The Revenue has grown by 7.77% in the last year.
ALSGD shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.41% yearly.
EPS 1Y (TTM)42.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.08%
Revenue 1Y (TTM)7.77%
Revenue growth 3Y1.8%
Revenue growth 5Y-7.41%
Sales Q2Q%5.94%

3.2 Future

ALSGD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.36% yearly.
ALSGD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.09% yearly.
EPS Next Y28.57%
EPS Next 2Y25.36%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year10.39%
Revenue Next 2Y17.09%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALSGD.PA Yearly Revenue VS EstimatesALSGD.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
ALSGD.PA Yearly EPS VS EstimatesALSGD.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALSGD. In the last year negative earnings were reported.
Also next year ALSGD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALSGD.PA Price Earnings VS Forward Price EarningsALSGD.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALSGD.PA Per share dataALSGD.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02 0.04 -0.04 0.06

4.3 Compensation for Growth

A more expensive valuation may be justified as ALSGD's earnings are expected to grow with 25.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.36%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALSGD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPINEGUARD SA

EPA:ALSGD (7/11/2025, 7:00:00 PM)

0.0899

0 (-3.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-15 2025-04-15
Earnings (Next)07-09 2025-07-09
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap5.59M
Analysts84.44
Price Target0.64 (611.9%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-15.44%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.2
P/FCF N/A
P/OCF N/A
P/B 1.43
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.06
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0.07
BVpS0.06
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.45%
ROE -78.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.8%
FCFM N/A
ROA(3y)-32.05%
ROA(5y)-28.87%
ROE(3y)-64.95%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.62%
GM growth 5Y-2.09%
F-Score4
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 117.97%
Cap/Sales 7.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.97
Quick Ratio 0.69
Altman-Z -6.19
F-Score4
WACC8.11%
ROIC/WACCN/A
Cap/Depr(3y)225.04%
Cap/Depr(5y)170.18%
Cap/Sales(3y)14.39%
Cap/Sales(5y)11.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.08%
EPS Next Y28.57%
EPS Next 2Y25.36%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.77%
Revenue growth 3Y1.8%
Revenue growth 5Y-7.41%
Sales Q2Q%5.94%
Revenue Next Year10.39%
Revenue Next 2Y17.09%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.26%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y41.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.99%
OCF growth 3YN/A
OCF growth 5YN/A